Peculiarities of molecular events in human glial tumors revealed by serial analysis of gene expression (SAGE)

Experimental Oncology

Volumn 26, Issue 3, 2004, Pages 196-204

  Kavsan, Vadym ^a   Shostak, Katherina ^a   Dmitrenko, Vladimir ^a   Chausovskiy, Timur ^a   Zozulya, Yury ^b   Demotes Mainard, Jacques ^c  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^b Institute of Neurosurgery Ams of Ukraine   (Ukraine)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Glial tumors; Glioblastoma; Serial analysis of gene expression (SAGE); Tumor markers

Indexed keywords

BETA 2 MICROGLOBULIN; CALCIUM BINDING PROTEIN; CD99 ANTIGEN; COLLAGEN TYPE 6; COMPLEMENTARY DNA; GALECTIN 3; HLA ANTIGEN CLASS 1; MESSENGER RNA; OSTEONECTIN; PROTEIN; RIBOSOME PROTEIN; RIBOSOME PROTEIN S29; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; SERIAL ANALYSIS OF GENE EXPRESSION; BRAIN REGION; CELL TRANSFORMATION; CONTROLLED STUDY; GENE LIBRARY; MOLECULAR EVOLUTION; PROTEIN FOLDING;

ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; GLIOBLASTOMA; HUMANS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 7044227569     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Schoenberg BS. Epidemiology of central nervous system tumor. In: Oncology of the Nervous System. Walker MD, ed. Boston: Niihoff, 1983: 1-30.
2. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1999; 1: 44-51.
3. Levin AL, Sheline GE, Gutin PH. Neoplasms of the central nervous system. In: Cancer: Principles and Practice of Oncology (3rd ed.). Devita S, Hellman S, Rosenberg SA, eds. Philadelphia: Lippincott, 1989: 1557-611.
4. Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD, Strausberg RL, Riggins GJ. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 2000; 10: 1393-402.
5. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-25.
6. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987; 162: 156-9.
7. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ. A public database for gene expression in human cancers. Cancer Res 1999; 59: 5403-7.
8. Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS. Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia 2000; 32: 146-54.
9. Ljubimova JY, Lakhter A, Loksh A, Yong WH, Riedinger MS, Miner JH, Sorokin ML, Ljubimov AV, Black KL. Overexpression of a4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res 2001; 61: 5601-10.
10. Markert JM, Fuller KM, Gillespie GY, Bubien JK, Mclean LA, Hon RL, Lee K, Gullans SR, Mapstone TB, Benos DJ. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001; 5: 21-33.
11. Shostak K, Labunskyy V, Dmitrenko V, Malisheva T, Shamayev M, Rozumenko V, Zozulya Y, Zehetner G, Kavsan V. HC gp-39 gene is upregulated in glioblastomas. Cancer Lett 2003; 198: 203-10.
12. Mulla A, Christian HC, Solito E, Mendoza N, Morris JF, Buckingham JC. Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma. Clin Endocrinol 2004; 60: 107.
13. Zhang H, Liew CC, Marshall KW. Microarray analysis reveals the involvement of beta-2 microglobulin (B2M) in human osteoarthritis. Osteoarthritis Cartilage 2002; 10: 950-60.
14. Selli C, Cozzolino F, Carini M, Lenzi R, Vercelli D. Serum beta 2 microglobulin levels in patients with renal cell carcinoma. Urol Res 1984; 12: 261-3.
15. Cooper MJ, Hutchins GM, Mennie RJ, Israel MA. Beta 2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation. Cancer Res 1990; 50: 3694-700.
16. Remes K, Tienhaara A, Pelliniemi TT. Effects of alpha-interferon on serum beta-2-microglobulin. Leuk Lymphoma 1996; 21: 233-8.
17. Scudla V, Budikova M, Fischerova E, Raska I, Vavrdova V. Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease. Vnitr Lek 1991; 37: 479-87.
18. Maesawa C, Iijima S, Sato N, Yoshinori N, Suzuki M, Tarusawa M, Ishida K, Tamura G, Saito K, Masuda T. Esophageal extraskeletal Ewing's sarcoma. Hum Pathol 2002; 33: 130-2.
19. Vasdev N, Nayak NC. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour. Indian J Pathol Microbiol 2003; 46: 625-9.
20. Dworzak MN, Froschl G, Printz D, Zen LD, Gaipa G, Ratei R, Basso G, Biondi A, Ludwig WD, Gadner H. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia 2004; 18: 703-8.
21. Zamecnik M, Michal M. Nuchal-type fibroma is positive for CD34 and CD99. Am J Surg Pathol 2001; 25: 970.
22. Hamilton D, Mallinger R, Millesi H, Engel A, Baumgartner G, Raderer M. Modulation of CD99/MIC2 expression of human AHTO-7 osteoblasts by carcinoma cell line-conditioned media. Anticancer Res 2001; 21: 3909-13.
23. Pelosi G, Fraggetta F, Sonzogni A, Fazio N, Cavallon A, Viale G. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. Virhovs Arch 2000; 437: 270-4.
24. Tsang WY, Seneviratne S, Pau MY. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors. Am J Surg Pathol 1995; 19: 1115-23.
25. Choi YL, Kim HS, Ahn G. Immunoexpression of inhibin alpha subunit, inhibin/activin betaA subunit and CD99 in ovarian tumors. Arch Pathol Lab Med 2000; 124: 563-9.
26. Luttges J, Mentzel T, Hubner G, Kloppel G. Solitary fibrous tumour of the pancreas: a new member of the small group of mesenchymal pancreatic tumours. Virchows Arch 1999; 435: 37-42.
27. Halliday BE, Slagel DD, Elsheikh TE, Silverman JF. Diagnostic utility of MIC-2 immunocytochemical staining in the differential diagnosis of small blue cell tumors. Diagn Cytopathol 1998; 19: 410-6.
28. Kuo, H-J, Maslen, CL, Keene DR, Glanville RW. Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J Biol Chem 1997; 272: 26522-9.
29. Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad O, Engebraaten O. Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res 2004; 294: 130-9.
30. Redondo M, Garcia J, Villar E, Rodrigo I, Perea-Milla E, Serrano A, Morell M. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003; 34: 1283-9.
31. Cabrera T, Pedrajas G, Cozar JM, Garrido A, Vicente J, Tallada M, Garrido F. HLA class I expression in bladder carcinomas. Antigens 2003; 62: 324-7.
32. Sarkar AK, Burlingame SM, Zang YQ, Dulai V, Hicks MJ, Strother DR, Nuchtern JG. Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes. Immunother 2001; 24: 305-11.
33. Feenstra M, Veltkamp M, van Kuik J, Wiertsema S, Slootweg P, van den Tweel J, de Weger R, Tilanus M. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Eur J Immunol 1999; 29: 3925-35.
34. Lefebvre S, Moreau P, Dausset J, Carosella ED, Paul P. Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIIT. Placenta 1999; 20: 293-301.
35. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996; 73: 148-53.
36. Redondo M, Ruiz-Cabello F, Concha A, Cabrera T, Perez-Ayala M, Oliva MR, Garrido F. Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res 1991; 51: 2463-8.
37. Li Q, Chan SH, Ren EC. Studies of HLA-A and DR locus deletions in human liver cancer cell lines by PCR. Eur J Cancer 1996; 32A: 371-2.
38. Moller P, Momburg F, Koretz K, Moldenhauer G, Herfarth C, Otto HF, Hammerling GJ, Schlag P. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res 1991; 51: 729-36.
39. Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M. Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer 2003; 105: 430-1; author reply 432-3.
40. Wu AH, Hall WA, Low WC. Identification of HLA a*0201 glioblastoma multiform cell lines for immunotherapy by PCR-SSP and DNA sequencing. J Neurooncol 2004; 66: 1-8.
41. Machulla HK, Steinborn F, Schaaf A, Heidecke V, Rainov NG. Brain glioma and human leukocyte antigens (HLA) - is there an association. J Neurooncol 2001; 52: 253-61.
42. Kato Y, Lewalle JM, Baba Y, Tsukuda M, Sakai N, Baba M, Kobayashi K, Koshika S, Nagashima Y, Frankenne F, Noel A, Foidart JM, Hata RI. Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 2001; 287: 422-6.
43. Dmitrenko VV, Shostak KO, Boyko OI, Simirenko OE, Gundorov IS, Khomenko OV, Rozumenko VD, Malisheva TA, Shamaev MI, Zozulya YA, Kavsan VM. Activation of the expression of SPARC gene early in astrocytic glioma progression. Biopolymeres and Cell 2004 (in press).
44. Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T, Gutierrez JA. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 1998; 57: 1112-21.
45. Ishii M, Hashimoto S, Tsutsumi S, Wada Y, Matsushima K, Kodama T, Aburatani H. Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. Genomics 2000; 68: 136-43.
46. Swaroop A, Hogan BLM, Franke U. Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics 1988; 2: 37-47.
47. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001; 158: 1639-51.
48. Strik HM, Deininger MH, Frank B, Schluesener HJ, Meyermann R. Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol 2001; 53: 13-20.
49. Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, Graeber S, Herzog V, Pietsch T, Wiestler OD, Probstmeier R. Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res 2000; 60: 45-57.
50. Zhou ZD, Bao L, Liu DG, Li MQ, Ge YZ, Huang YL, Liu WY. Low content of protein S29 in ribosomes of human lung cancer cell line a549: detected by two-dimensional electrophoresis. Protein Pept Lett 2003; 10: 91-7.
51. Kondoh N, Noda M, Fisher RJ, Schweinfest CW, Papas TS, Kondoh A, Samuel KP, Oikawa T. The S29 ribosomal protein increases tumor suppressor activity of K rev-1 gene on v-K ras-transformed NIH3T3 cells. Biochim Biophys Acta 1996; 1313: 41-6.
52. Khanna N, Sen S, Sharma H, Singh N. S29 ribosomal protein induces apoptosis in H520 cells and sensitizes them to chemotherapy. Biochem Biophys Res Commun 2003; 304: 26-35.
53. Coppock D, Kopman C, Gudas J, Cina Poppe DA. Regulation of the quiescence-induced genes: quiescin Q6, decorin, and ribosomal protein S29. Biochem Biophys Res Commun 2000; 269: 604-10.
54. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson HF, Powell SM. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002; 62: 6823-6.
55. Teratani T, Watanabe T, Kuwahara F, Kumagai H, Kobayashi S, Aoki U, Ishikawa A, Arai K, Nozawa R. Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma. Cancer Lett 2002; 175: 71-7.
56. Greenfield JJ, High S. The Sec61 complex is located in both the ER and the ER-Golgi intermediate compartment. J Cell Sci 1999; 112: 1477-86.
57. Van den Berg B, Clemons WM Jr, Collinson I, Modis Y, Hartmann E, Harrison SC, Rapoport TA. X-ray structure of a protein-conducting channel. Nature 2004; 427: 36-44.
58. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, Khan F, Paskins L. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 2001; 84: 1512-9.
59. Plate KH. Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 1999; 58: 313-20.
60. Dmitrenko VV, Shostak KO, Garifulin OM, Zozulya YA, Kavsan VM. Changes of gene expression in human astrocytic brain tumors. Exp Oncol 1998; 20: 191-7.